Sunshine Net Income Per E B T from 2010 to 2024

SBFMW Stock  USD 0.23  0.09  64.29%   
Sunshine Biopharma Net Income Per E B T yearly trend continues to be fairly stable with very little volatility. Net Income Per E B T will likely drop to 0.77 in 2024. During the period from 2010 to 2024, Sunshine Biopharma Net Income Per E B T regression line of quarterly data had mean square error of  0.06 and geometric mean of  1.13. View All Fundamentals
 
Net Income Per E B T  
First Reported
2010-12-31
Previous Quarter
1.09612718
Current Value
0.77
Quarterly Volatility
0.30136234
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sunshine Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sunshine Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 148.9 K, Other Operating Expenses of 30.3 M or Total Operating Expenses of 13.8 M, as well as many indicators such as Price To Sales Ratio of 0.26, Dividend Yield of 0.0 or PTB Ratio of 0.3. Sunshine financial statements analysis is a perfect complement when working with Sunshine Biopharma Valuation or Volatility modules.
  
Check out the analysis of Sunshine Biopharma Correlation against competitors.
For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.

Latest Sunshine Biopharma's Net Income Per E B T Growth Pattern

Below is the plot of the Net Income Per E B T of Sunshine Biopharma Warrant over the last few years. It is Sunshine Biopharma's Net Income Per E B T historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sunshine Biopharma's overall financial position and show how it may be relating to other accounts over time.
Net Income Per E B T10 Years Trend
Slightly volatile
   Net Income Per E B T   
       Timeline  

Sunshine Net Income Per E B T Regression Statistics

Arithmetic Mean1.19
Geometric Mean1.13
Coefficient Of Variation25.42
Mean Deviation0.23
Median1.36
Standard Deviation0.30
Sample Variance0.09
Range1.0332
R-Value(0.63)
Mean Square Error0.06
R-Squared0.39
Significance0.01
Slope(0.04)
Total Sum of Squares1.27

Sunshine Net Income Per E B T History

2024 0.77
2023 1.1
2022 1.01
2021 1.03
2020 0.32

About Sunshine Biopharma Financial Statements

Sunshine Biopharma investors use historical fundamental indicators, such as Sunshine Biopharma's Net Income Per E B T, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Sunshine Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Income Per E B T 1.10  0.77 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Sunshine Stock Analysis

When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.